Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17128643rdf:typepubmed:Citationlld:pubmed
pubmed-article:17128643lifeskim:mentionsumls-concept:C0005684lld:lifeskim
pubmed-article:17128643lifeskim:mentionsumls-concept:C2936643lld:lifeskim
pubmed-article:17128643lifeskim:mentionsumls-concept:C2911685lld:lifeskim
pubmed-article:17128643lifeskim:mentionsumls-concept:C0521116lld:lifeskim
pubmed-article:17128643lifeskim:mentionsumls-concept:C1519814lld:lifeskim
pubmed-article:17128643pubmed:issue3lld:pubmed
pubmed-article:17128643pubmed:dateCreated2006-11-28lld:pubmed
pubmed-article:17128643pubmed:abstractTextUrinary bladder cancer arises in the transitional cell epithelium of the bladder. In the United States, it is the fourth most common tumor in men and the eighth most common tumor in women. Here, Dr Sonpavde reviews the risk factors for bladder cancer, its diagnosis, the latest concepts of its molecular characteristics and metastatic potential, and current strategies to treat this common disease. He focuses in particular on management of transitional cell carcinoma, which is responsible for about 95% of cases.lld:pubmed
pubmed-article:17128643pubmed:languageenglld:pubmed
pubmed-article:17128643pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17128643pubmed:citationSubsetIMlld:pubmed
pubmed-article:17128643pubmed:statusMEDLINElld:pubmed
pubmed-article:17128643pubmed:issn0032-5481lld:pubmed
pubmed-article:17128643pubmed:authorpubmed-author:SonpavdeGuruGlld:pubmed
pubmed-article:17128643pubmed:issnTypePrintlld:pubmed
pubmed-article:17128643pubmed:volume119lld:pubmed
pubmed-article:17128643pubmed:ownerNLMlld:pubmed
pubmed-article:17128643pubmed:authorsCompleteYlld:pubmed
pubmed-article:17128643pubmed:pagination30-7lld:pubmed
pubmed-article:17128643pubmed:meshHeadingpubmed-meshheading:17128643...lld:pubmed
pubmed-article:17128643pubmed:meshHeadingpubmed-meshheading:17128643...lld:pubmed
pubmed-article:17128643pubmed:meshHeadingpubmed-meshheading:17128643...lld:pubmed
pubmed-article:17128643pubmed:meshHeadingpubmed-meshheading:17128643...lld:pubmed
pubmed-article:17128643pubmed:meshHeadingpubmed-meshheading:17128643...lld:pubmed
pubmed-article:17128643pubmed:meshHeadingpubmed-meshheading:17128643...lld:pubmed
pubmed-article:17128643pubmed:meshHeadingpubmed-meshheading:17128643...lld:pubmed
pubmed-article:17128643pubmed:meshHeadingpubmed-meshheading:17128643...lld:pubmed
pubmed-article:17128643pubmed:meshHeadingpubmed-meshheading:17128643...lld:pubmed
pubmed-article:17128643pubmed:meshHeadingpubmed-meshheading:17128643...lld:pubmed
pubmed-article:17128643pubmed:articleTitleBladder cancer update. Current evaluation methods and standard of care.lld:pubmed
pubmed-article:17128643pubmed:affiliationTexas Oncology, PA, Deke Slayton Cancer Center, Webster 77598, USA. guru.sonpavde@usoncology.comlld:pubmed
pubmed-article:17128643pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17128643pubmed:publicationTypeReviewlld:pubmed